Welcome!

Microsoft Cloud Authors: Liz McMillan, Elizabeth White, Mihai Corbuleac, Pat Romanski, David Bermingham

News Feed Item

Vermillion Reports Third Quarter 2012 Results

AUSTIN, Texas, Nov. 12, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported financial and operational results for the third quarter ended September 30, 2012.

Q3 2012 Operational Highlights

  • In Q3, the volume of OVA1®, the company's flagship diagnostic test designed to help differentiate benign from malignant ovarian masses, was in line with management's forecast at approximately 4,100 tests.
  • Submitted a manuscript on the OVA500 pivotal study by principal investigator, Dr. Robert Bristow of UC Irvine. This second prospective study of OVA1 confirmed the test's high sensitivity, at 96% and negative predictive value, at 98%, substantiating clinical results reported in the previous pivotal study by Dr. Fred Ueland of U. Kentucky. This is important since doctors, payers and professional societies make their decisions, in part, on the publication of multiple independent clinical studies. The study also reported that OVA1 correctly detected 91% of early stage cancers. Combined with the result from the first study, OVA1 correctly identified 78 out of 84 early-stage ovarian malignancies among more than 1,000 patients evaluated, for a combined risk stratification sensitivity of approximately 93%.
  • Initiated a joint program with Quest Diagnostics focused in six states to improve OVA1 physician reorder rates by reestablishing OVA1 as 'top-of-mind,' as well as launched a Claims Assistance Program to assist physicians with the appeals process.
  • Published a peer-reviewed manuscript titled "A Validated Biomarker Panel To Identify Peripheral Artery Disease" in Vascular Medicine, a premier international journal featuring primary research articles and reviews on vascular disease, diagnosis, and treatment. The 1,025 patient study validated earlier biomarker discovery results in an intended use population, by identifying 85% (17 of 20) of PAD patients missed by the Framingham Risk Score's high-risk cutoff.

Q3 2012 Financial Highlights
Total revenue in the third quarter of 2012 was $319,000, comprised of $205,000 in OVA1 sales and $114,000 in license fees from Quest Diagnostics. Product revenue from OVA1 sales in the third quarter of 2012 was flat as compared to the same year-ago quarter.

Total operating expenses decreased in the third quarter to $2.6 million from $4.8 million in the same year-ago quarter. The decrease was primarily the result of lower clinical trial costs due to Vermillion's Peripheral Artery Disease (PAD) multi-marker intended use study having been completed in 2011, lower legal expenses, and continuing cost containment with improved operational efficiency. This also resulted in lower operating expenses for the nine months ended September 30, 2012, which totaled $9.0 million as compared to $15.5 million in the same year-ago period.

Net loss for the third quarter was $2.0 million or $(0.13) per share, an improvement from a loss of $4.7 million or $(0.31) per share in the same year-ago quarter. The third quarter of 2012 net loss included a $0.3 million gain for a payment received on litigation settlement. For the nine months ended September 30, 2012, net loss was $5.8 million or $(0.39) per share, as compared to $14.7 million or $(1.04) per share in the same year-ago period.

As of September 30, 2012, the company's cash and cash equivalents totaled $16.3 million as compared to $18.3 million at June 30, 2012. The company utilized $2.3 million in cash in the third quarter of 2012, offset by the $0.3 million payment received on litigation settlement during the third quarter. Management expects $2.0 million to $2.5 million in cash utilization during the fourth quarter of 2012 excluding approximately $5.9 million paid to Quest Diagnostics under the Secured Line of Credit Agreement in October 2012.

Management Commentary
"In Q3, our OVA500 pivotal study further established the valuable clinical utility of OVA1, with its high sensitivity and negative predictive value," said Gail S. Page, Vermillion's president and chief executive officer. "The manuscript of the study has recently been submitted for publication, and we plan to use the publication to aid in expanding OVA1's clinical adoption and increasing positive coverage decisions from national payers.

"Our recent loan repayment to Quest deleverages our balance sheet as well as demonstrates the success of our partnership agreement, which was designed to help bring Vermillion to this pivotal stage of its growth and development. Quest has been an important and supportive partner for many years, and we look forward to continuing our close relationship. In fact, together we successfully initiated a program focused in six states to improve OVA1 physician reorder rates by reestablishing OVA1 as 'top-of-mind.'

"Our CPT code becomes effective this January and will be priced for the first year by CMS using their gap-fill process. CMS uses the gap-fill method when no comparable molecular diagnostic exists. It determines a reimbursement amount for the first year by multiple factors, including what other payers might be paying. In anticipation of this process eventually occurring, during the early-stage of the OVA1 launch we secured reimbursement from Medicare at $516.25 per test, which is a common benchmark for reimbursement of a new diagnostic. We have also established another benchmark from the Department of Defense list price at $650.00 per test. We expect this new CPT code to streamline the claims process and strengthen our reimbursement results.

"As we wrap-up 2012 and prepare for the new year, we will work towards greater adoption by focusing on reimbursement, physician awareness and market education. Vermillion remains strongly committed to advancing the market adoption of OVA1 as the most sensitive ovarian cancer diagnostic on the market today. As we further develop our ovarian cancer franchise, we plan to expand beyond clinical labs to address the broader market, including hospitals and other points-of-care."

CEO Succession Plan
As previously announced, the company's board has formed a succession committee of independent directors to oversee the process of identifying and selecting a new CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates. Gail Page will continue in her role until the new CEO is appointed, and after assisting in the transition, plans to act as a strategic advisor for the company as required by the board of directors.

Conference Call and Webcast
Vermillion will hold a conference call to discuss its third quarter financial results later today, Monday, November 12, 2012 at 4:30 p.m. Eastern time. Management will host the presentation, followed by a question and answer period.

Date: Monday, November 12, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-736-4610
International: 1-212-231-2900
Conference ID#: 21607929
Webcast: http://edge.media-server.com/m/p/saaeq3ma/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call and until November 26, 2012.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21607929

About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

Citings:
1)     Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011
2)     Miller R, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Forward-Looking Statement:
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the U.S. Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.

Investor Relations Contact:
Liolios Group
Scott Liolios or Ron Both
Tel 949-574-3860
[email protected]

 

Vermillion, Inc.

Consolidated Balance Sheets

(Amounts in Thousands, Except Share and Par Value Amounts)

(Unaudited)


 September 30,


December 31,


2012


2011

Assets




Current assets:




Cash and cash equivalents

$          16,328


$      22,477

Accounts receivable

128


99

Prepaid expenses and other current assets

263


317

Total current assets

16,719


22,893

Property and equipment, net

163


216

Other assets

-


2

Total assets

$          16,882


$      23,111





Liabilities and Stockholders' Equity




Current liabilities:




Accounts payable

$               661


$        1,331

Accrued liabilities

1,870


2,592

Short-term debt

7,000


7,000

Deferred revenue

1,076


553

Total current liabilities

10,607


11,476

Deferred revenue

883


1,224

Other liabilities

-


52

Total liabilities

11,490


12,752

Commitments and contingencies




Stockholders' equity:




Preferred stock, $0.001 par value, 5,000,000 shares authorized,

   none issued and outstanding at  September 30, 2012 and

   December 31, 2011, respectively




-


-

Common stock, $0.001 par value, 150,000,000 shares authorized

  at  September 30, 2012 and December 31, 2011; 15,095,288 and

  14,900,831 shares issued and outstanding at September 30, 2012

  and December 31, 2011, respectively




15


15

Additional paid-in capital

327,601


326,796

Accumulated deficit

(322,070)


(316,299)

Accumulated other comprehensive loss

(154)


(153)

Total stockholders' equity

5,392


10,359

Total liabilities and stockholders' equity

$          16,882


$     23,111





         

 

Vermillion, Inc.

Consolidated Statements of Operations

(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)



Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011









Revenue:








Product

$ 205


$ 206


$ 611


$ 714

License

114


114


341


341

Total revenue

319


320


952


1,055









Cost of revenue:








Product

33


26


99


105

Total cost of revenue

33


26


99


105

Gross profit

286


294


853


950









Operating expenses:








Research and development(1)

429


1,370


1,883


4,219

Sales and marketing(2)

1,082


1,499


3,722


4,320

General and administrative(3)

1,073


1,952


3,381


6,982

Total operating expenses

2,584


4,821


8,986


15,521

Loss from operations

(2,298)


(4,527)


(8,133)


(14,571)

Interest income

7


18


23


55

Interest expense

(66)


(100)


(197)


(330)

Gain on sale of instrument business

50


-


1,830


-

Gain on litigation settlement, net

331


-


710


-

Change in fair value of warrants

-


32


-


374

Reorganization items

-


(42)


88


(74)

Other expense, net

(45)


(32)


(92)


(109)

Loss before income taxes

(2,021)


(4,651)


(5,771)


(14,655)

Income tax benefit (expense)

-


-


-


-

Net loss

$ (2,021)


$ (4,651)


$ (5,771)


$ (14,655)

Net loss per share - basic and diluted

$   (0.13)


$   (0.31)


$   (0.39)


$     (1.04)

Comprehensive loss

$ (2,021)


$ (4,650)


$ (5,772)


$ (14,652)









Weighted average common shares used to compute basic and diluted net loss per common share

15,057,027


14,820,694


14,972,877


14,041,549









Non-cash stock-based compensation expense included in operating expenses:





(1) Research and development

$ 25


$ 181


$ 99


$ 590

(2) Sales and marketing

55


40


148


122

(3) General and administrative

168


211


552


2,264

 

SOURCE Vermillion, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 18th International CloudExpo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
SYS-CON Events announced today that EastBanc Technologies will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. EastBanc Technologies has been working at the frontier of technology since 1999. Today, the firm provides full-lifecycle software development delivering flexible technology solutions that seamlessly integrate with existing systems – whether on premise or cloud. EastBanc Technologies partners with p...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today BZ Media LLC has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. BZ Media LLC is a high-tech media company that produces technical conferences and expositions, and publishes a magazine, newsletters and websites in the software development, SharePoint, mobile development and Commercial Drone markets.
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, will discuss the importance of WebRTC and how it enables companies to fo...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
IoT generates lots of temporal data. But how do you unlock its value? How do you coordinate the diverse moving parts that must come together when developing your IoT product? What are the key challenges addressed by Data as a Service? How does cloud computing underlie and connect the notions of Digital and DevOps What is the impact of the API economy? What is the business imperative for Cognitive Computing? Get all these questions and hundreds more like them answered at the 18th Cloud Expo...
SYS-CON Events announced today the How to Create Angular 2 Clients for the Cloud Workshop, being held June 7, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified. Now it’s a component-based well-performing framework. The immersive one-day workshop led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and...
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...
SYS-CON Events announced today that BMC Software has been named "Siver Sponsor" of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. BMC is a global leader in innovative software solutions that help businesses transform into digital enterprises for the ultimate competitive advantage. BMC Digital Enterprise Management is a set of innovative IT solutions designed to make digital business fast, seamless, and optimized from mainframe to mo...
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life ...